Hypoglycemic Potential of Garcinia Cambogia (Garcinia Gummi-gutta (L.) N.Robson) Rind Powder Among Pre-diebetic Obese Patients

NCT07419074 | Completed DMC

• 1 other identifier: UOL/IREB/25/12/0053
• Study Type: interventional
• Target: 90
• Locations: 1 country
• Sites: 1

Brief Summary

Garcinia cambogia, rich in hydroxycitric acid (HCA), has been suggested to promote weight loss and improve metabolic parameters. Evidence regarding its efficacy in pre-diabetic obese adults remains limited. Objective: To evaluate the effects of Garcinia cambogia rind powder supplementation on anthropometric, glycemic, lipid, hepatic, and renal parameters in pre-diabetic obese adults.

Conditions

Lipid Profile

Keywords

Garcinia cambogia, Garcinia gummi-gutta, hypoglycemic effect, pre-diabetic, obesity, hydroxycitric acid (HCA), glucose metabolism

Outcome Measures

Primary Outcomes (1)

• Weight

  12 weeks

Secondary Outcomes (2)

• Lipid profile

  12 weeks

• fasting glucose

  12 weeks

Study Arms (3)

Placebo group

PLACEBO COMPARATOR

Starch capsule once a day

Dietary Supplement: Garcinia cambogia rind powder

T1

EXPERIMENTAL

100mg/day of Garcinia cambogia rind powder

Dietary Supplement: Garcinia cambogia rind powder

T2

EXPERIMENTAL

200mg/day of Garcinia cambogia rind powder

Dietary Supplement: Garcinia cambogia rind powder

Interventions

Garcinia cambogia rind powder DIETARY_SUPPLEMENT

Once a day

Placebo group

Eligibility Criteria

• Age: 30 Years - 60 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Participants of both genders were included if they were aged 30-60 years,
• body mass index (BMI) ≥30 kg/m²,
• Individuals with HbA1c levels ranging from 5.7% to 10% were selected, .indicating pre-diabetic to diabetic status. Participants were required to have a .body mass index (BMI) of 25 kg/m² or higher

You may not qualify if:

• Participants who were diagnosed with type 1, pregnant or lactating,
• chronic liver, kidney, or cardiovascular disease,
• history of hepatotoxicity or gastrointestinal disorders,
• using weight-loss supplements, steroids, or lipid-lowering drugs, or had a known allergy to Garcinia cambogia

Sponsors & Collaborators

• University of Lahore: lead

Study Sites (1)

Sana Noreen

Lahore, 54000, Pakistan

Location

Related Links

• Randomized trial on weight and lipid profile of obese by formulation from Garcinia cambogia

MeSH Terms

Conditions

Glucose Intolerance; Obesity; Adenoma, Liver Cell

Condition Hierarchy (Ancestors)

Hyperglycemia; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Overweight; Overnutrition; Nutrition Disorders; Body Weight; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Adenoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Liver Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Digestive System Diseases; Liver Diseases

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: HEALTH SERVICES RESEARCH
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 11, 2026
• First Posted: February 18, 2026
• Study Start: September 1, 2025
• Primary Completion: November 24, 2025
• Study Completion: January 1, 2026
• Last Updated: February 18, 2026

Record last verified: 2025-10

Data Sharing

• IPD Sharing: Will not share

Locations

PA (1)